Skip to Content

'
Nizar M. Tannir, MD, FACP

Present Title & Affiliation

Primary Appointment

Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston
Deputy Department Chair, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

There has been significant progress made in the treatment of clear-cell renal cell carcinoma (RCC), with several targeted agents now approved.  However, the vast majority of patients develop progressive disease within a year. Despite the clinical efficacy of targeted agents, significant toxicity hampers patient benefit, and <30% of patients with metastatic RCC survive >five years. Furthermore, insight into the biology of non-clear cell RCC subtypes has lagged behind clear-cell RCC, with few relevant targets identified. Currently, there is no established effective therapy for this diverse group of non-clear cell RCC subtypes. Therapeutic strategies using immune checkpoint antibodies are revolutionizing the treatment of many cancers including RCC, but at best 50% of patients with metastatic RCC respond to the combination of anti-PD-1 and anti-CTLA-4 antibodies. The long-term follow-up of patients with metastatic RCC treated with these novel immune approaches will be awaited to assess their curative potential. 

My research focus in RCC is in the following areas:

  • Molecular and clinical characterization of non-clear cell RCC subtypes, particularly translocation RCC and renal medullary carcinoma
  • Design and conduct of informative, biology-driven clinical trials for clear-cell and non-clear cell RCC
  • Identification of circulating and tissue-based biomarkers of response to targeted agents and immune checkpoint antibodies in patients with clear-cell and non-clear cell RCC

The projects outlined above are currently being carried out in the context of several investigator-initiated, approved, and funded clinical and laboratory trials in metastatic clear-cell and non-clear cell RCC, on which I serve as principal investigator.

Office Address

The University of Texas MD Anderson Cancer Center
1155 Pressler Street
Unit Number: 1374
Houston, TX 77030
Room Number: CPB7.3470
Phone: (713) 563-7265
Fax: 713-745-0422
Email: ntannir@mdanderson.org

Education & Training

Degree-Granting Education

1979 American University of Beirut, Beirut, Lebanon, MD, Medicine
1975 American University of Beirut, Beirut, Lebanon, BS, Biology/Chemistry

Postgraduate Training

8/2000-11/2000 Clinical Fellowship, Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
7/1985-6/1986 Clinical Fellowship, Hematology, University of Medicine and Dentistry of New Jersey, Newark, NJ
7/1981-6/1984 Clinical Fellowship, Medical Oncology, The University of Texas MD Anderson Hospital and Tumor Institute, Houston, TX

Board Certifications

11/2000 American Board of Internal Medicine/Hematology
11/2000 American Board Internal Medicine/Medical Oncology
1/1987 American Board Internal Medicine/Medical Oncology
1/1986 American Board of Internal Medicine/Hematology
1/1985 American Board of Internal Medicine

Experience/Service

Academic Appointments

Associate Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 9/2007-8/2014
Assistant Professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas M.D. Anderson Cancer Center, Houston, TX, 3/2001-8/2007
Visiting Scientist, Department of Leukemia, Division of Cancer Medicine, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 5/2000-7/2000

Administrative Appointments/Responsibilities

Director, Genitourinary Medical Oncology Clinic, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008-present
Director, Kentucky Cancer Clinic, Hazard, KY, 11/1997-12/1999
Voluntary Faculty, University of Kentucky, Lexington, KY, 11/1986-12/1999

Other Appointments/Responsibilities

Private Practice; Hematology Oncology, Appalachian Regional Medical Center, Hazard, KY, 11/1986-12/1999

Institutional Committee Activities

Chair, Division of Cancer Medicine Clinical Competency Committee, 1/2014-present
Member, Division of Cancer Medicine Clinical Competency Committee, 1/2013-12/2013
Member, Clinical Research and Patient Care Committee, 9/2011-present
Member, Division of Cancer Medicine Hematology/Oncology Fellowship Program Steering Committee, 9/2009-present

Honors and Awards

2013 Division of Cancer Medicine Hematology/Oncology Fellowship Program 2013 "Teacher of the Year", The University of Texas MD Anderson Cancer Center
2013 Gerald P. Bodey Award for Excellence in Education, Division of Cancer Medicine Recognition and Awards Program
2012 Top Doctor 2012, US News and World Report
2012 Division of Cancer Medicine Hematology/Oncology Fellowship Program 2012 "Teacher of the Year", The University of Texas MD Anderson Cancer Center
2011 Top Doctor 2011, US News and World Report
2010 Division of Cancer Medicine Hematology/Oncology Fellowship Program 2010 "Teacher of the Year", The University of Texas MD Anderson Cancer Center
2008 America's Top Oncologist, Guide to America's Top Oncologists
2008 Division of Cancer Medicine Hematology/Oncology Fellowship Program 2008 "Teacher of the Year", The University of Texas MD Anderson Cancer Center
2008 Vicente Valero LBJ Clinician-Educator of the Year, LBJ Hospital / The University of Texas M. D. Anderson Cancer Center
2001 Benefactors Award, Governor of Kentucky

Selected Publications

Peer-Reviewed Original Research Articles

1. Bilen MA, Johnson M, Mathew P, Pagliaro L, Araujo JC, Aparicio A, Corn P, Tannir N, Wong FC, Fisch MJ, Logothetis CJ, Tu S-M. A randomized phase II study of bone-targeted therapy containing strontium-89 in advanced castrate-sensitive prostate cancer. Cancer. In Press.
2. Jonasch E, Liu X-D, Yao J, Tripathi D, Ding Z, Xu Y, Sun M, Zhang J, Bai S, German P, Hoang A, Zhou L, Jonasch D, Zhang X, conti C, Efstathiou E, Tannir N, Eissa NT, Mills G, Walker C. Autophagy mediates HIF2α degradation and suppresses renal tumorigenesis. Oncogene. In Press.
3. Teegavarapu PS, Rao P, Matrana MR, Cauley DH, Wood CG, Tannir NM. Neuroendocrine Tumors of the Kidney: A Single Institution Experience. Clin Genitour Cancer. In Press. NIHMSID: NIHMSNIHMS618553.
4. Falchook GS, Wheler JJ, Naing A, Jackson EF, Janku F, Hong D, Ng CS, Tannir NM, Lawhorn KN, Huang M, Angelo LS, Vishwamitra D, Hess K, Howard AN, Parkhurst KL, Amin HM, Kurzrock R. Targeting hypoxia-inducible factor-1α (HIF-1α) in combination with antiangiogenic therapy: A phase I trial of bortezomib plus bevacizumab. Oncotarget. In Press.
5. Tu SM, Bilen M, Tannir NM. The scientific method: pillar and pitfall of cancer research. Can Med. In Press.
6. Shetty AV, Matrana MR, Atkinson BJ, Flaherty AL, Jonasch E, Tannir NM. Outcomes of patients with metastatic renal cell carcinoma and end-stage renal disease receiving dialysis and targeted therapies: A single institution experience. Clin Genitourin Cancer 12(5):348-53, 10/2014. e-Pub 1/18/2014. PMCID: PMC4160412.
7. Melkonian SC, Daniel CR, Hildebrandt MA, Tannir NM, Ye Y, Chow WH, Wood CG, Wu X. Joint Association of Genome-Wide Association Study-Identified Susceptibility Loci and Dietary Patterns in Risk of Renal Cell Carcinoma Among Non-Hispanic Whites. Am J Epidemiol 180(5):499-507, 9/1/2014. e-Pub 7/22/2014. PMCID: PMC4143080.
8. Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, de Vos S, Hamlin PA, Kim SK, Whiting NC, Gartner EM, Zhao B, Thompson JA. Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs. e-Pub 8/22/2014. PMID: 25142258.
9. Malouf GG, Zhang J, Yuan Y, Compérat E, Rouprêt M, Cussenot O, Chen Y, Thompson EJ, Tannir NM, Weinstein JN, Valero V, Khayat D, Spano JP, Su X. Characterization of long non-coding RNA transcriptome in clear-cell renal cell carcinoma by next-generation deep sequencing. Mol Oncol. e-Pub 7/25/2014. PMID: 25126716.
10. Jardim DL, de Melo Gagliato D, Falchook G, Zinner R, Wheler JJ, Janku F, Subbiah V, Piha-Paul SA, Fu S, Tannir N, Corn P, Tang C, Hess K, Roy-Chowdhuri S, Kurzrock R, Meric-Bernstam F, Hong DS. MET Abnormalities in Patients With Genitourinary Malignancies and Outcomes With c-MET Inhibitors. Clin Genitourin Cancer. e-Pub 7/3/2014. PMID: 25087088.
11. Malouf GG, Su X, Yao H, Gao J, Xiong L, He Q, Comperat E, Couturier J, Molinie V, Escudier B, Comparo P, Doss DJ, Thompson EJ, Khayat D, Wood CG, Yu W, Teh BT, Weinstein JN, Tannir NM. Next generation sequencing of translocation renal cell carcinomas reveals novel RNA splicing partners and frequent mutations of chromatin remodeling genes. Clin Cancer Res. e-Pub 6/4/2014. PMID: 24899691.
12. Prinsloo S, Wei Q, Scott SM, Tannir N, Jonasch E, Pisters L, Cohen L. Psychological states, serum markers and survival: associations and predictors of survival in patients with renal cell carcinoma. J Behav Med. e-Pub 6/17/2014. PMID: 24935017.
13. Hong DS, Gordon MS, Samlowski WE, Kurzrock R, Tannir N, Friedland D, Mendelson DS, Vogelzang NJ, Rasmussen E, Wu BM, Bass MB, Zhong ZD, Friberg G, Appleman LJ. A phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 12(3):167-177.e2, 6/2014. e-Pub 11/13/2013. PMID: 24365125.
14. Burch-Smith R, Tannir NM, Resetkova E, Tamboli P, Rao P. Collision tumor of the kidney composed of clear cell carcinoma and collecting duct carcinoma: report of a case with unusual morphology and clinical follow up. Chin J Cancer. e-Pub 3/4/2014. PMID: 24589208.
15. Milbury K, Spelman A, Wood C, Matin SF, Tannir N, Jonasch E, Pisters L, Wei Q, Cohen L. Randomized controlled trial of expressive writing for patients with renal cell carcinoma. J Clin Oncol 32(7):663-70, 3/1/2014. e-Pub 1/27/2014. PMCID: PMC3927735.
16. Atkinson BJ, Kalra S, Wang X, Bathala T, Corn P, Tannir NM, Jonasch E. Clinical outcomes in metastatic renal cell carcinoma patients treated with alternative sunitinib schedules. J Urol 191(3):611-8, 3/2014. e-Pub 9/7/2013. PMID: 24018239.
17. Atkinson BJ, Cauley DH, Ng C, Millikan RE, Xiao L, Corn P, Jonasch E, Tannir NM. Mammalian target of rapamycin (mTOR) inhibitor-associated non-infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes. BJU Int 113(3):376-82, 3/2014. e-Pub 12/2/2013. PMCID: PMC3944913.
18. Babaian KN, Merrill MM, Matin S, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Urol. e-Pub 2/8/2014. PMID: 24518767.
19. Karam JA, Devine CE, Urbauer DL, Lozano M, Maity T, Ahrar K, Tamboli P, Tannir NM, Wood CG. Phase 2 trial of neoadjuvant axitinib in patients with locally advanced nonmetastatic clear cell renal cell carcinoma. Eur Urol. e-Pub 2/2014. PMID: 24560330.
20. Vin H, Ching G, Ojeda SS, Adelmann CH, Chitsazzadeh V, Dwyer DW, Ma H, Ehrenreiter K, Baccarini M, Ruggieri R, Curry JL, Ciurea AM, Duvic M, Busaidy NL, Tannir NM, Tsai KY. Sorafenib suppresses JNK-dependent apoptosis through inhibition of ZAK. Mol Cancer Ther 13(1):221-9, 1/2014. e-Pub 10/29/2013. PMID: 24170769.
21. Verma J, Jonasch E, Allen PK, Weinberg JS, Tannir N, Chang EL, Mahajan A. The impact of tyrosine kinase inhibitors on the multimodality treatment of brain metastases from renal cell carcinoma. Am J Clin Oncol 36(6):620-4, 12/2013. e-Pub 8/2012. PMID: 22892430.
22. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn P, Pagliaro LC, Millikan RE, Charnsangave C, Jonasch E, Tannir NM. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with pazopanib after disease progression with other targeted therapies. Eur J Cancer 49(15):3169-75, 10/2013. e-Pub 6/2013. PMCID: PMC3882156.
23. Richey SL, Tamboli P, Ng CS, Lin E, Lim ZD, Araujo JC, Jonasch E, Sharma P, Pagliaro LC, Tannir NM. Phase II trial of pemetrexed plus gemcitabine in patients with locally advanced and metastatic nonclear cell renal cell carcinoma. Am J Clin Oncol 36(5):450-4, 10/2013. e-Pub 6/2012. PMCID: PMC3882166.
24. Yennurajalingam S, Frisbee-Hume S, Palmer JL, Delgado-Guay MO, Bull J, Phan AT, Tannir NM, Litton JK, Reddy A, Hui D, Dalal S, Massie L, Reddy SK, Bruera E. Reduction of cancer-related fatigue with dexamethasone: A double-blind, randomized, placebo-controlled trial in patients with advanced cancer. J Clin Oncol 31(25):3076-82, 9/1/2013. e-Pub 7/29/2013. PMID: 23897970.
25. Conter HJ, Lim ZD, Ng CS, Millikan RE, Tannir NM. Curability of poor-risk metastatic sarcomatoid renal cell carcinoma with the combination of gemcitabine, 5-fluorouracil, and interferon-alfa: A case report of a 55-year-old man with a 10-year complete remission. Clin Genitourin Cancer 11(3):370-3, 9/2013. e-Pub 5/2013. PMID: 23665133.
26. Malouf GG, Monzon FA, Couturier J, Molinié V, Escudier B, Camparo P, Su X, Yao H, Tamboli P, Lopez-Terrada D, Picken M, Garcia M, Multani AS, Pathak S, Wood CG, Tannir NM. Genomic heterogeneity of translocation renal cell carcinoma. Clin Cancer Res 19(17):4673-4684, 9/2013. e-Pub 7/2013. PMCID: PMC3882157.
27. Khoury JD, Tannir NM, Williams MD, Chen Y, Yao H, Zhang J, Thompson EJ, TCGA Network, Meric-Bernstam F, Medeiros LJ, Weinstein JN, Su X. Llandscape of DNA virus associations across human malignant cancers using RNA-seq: An analysis of 3775 cases. J Virol 87(16):8916-26, 8/2013. e-Pub 6/2013. PMCID: PMC3754044.
28. Anzalone CL, Cohen PR, Migden MR, Tannir NM. Mohs surgery in metastatic cancer: renal cell carcinoma solitary cutaneous metastasis and visceral tumor metastases to skin treated with microscopically controlled surgical excision. Int J Dermatol 52(7):856-61, 7/2013. e-Pub 5/2013. PMID: 23675612.
29. Aparicio AM, Harzstark AL, Corn PG, Wen S, Araujo JC, Tu SM, Pagliaro LC, Kim J, Millikan RE, Ryan C, Tannir NM, Zurita AJ, Mathew P, Arap W, Troncoso P, Thall PF, Logothetis CJ. Platinum-based chemotherapy for variant castrate-resistant prostate cancer. Clin Cancer Res 19(13):3621-30, 7/2013. e-Pub 5/2013. PMCID: PMC3699964.
30. Parker PA, Alba F, Fellman B, Urbauer DL, Li Y, Karam JA, Tannir N, Jonasch E, Wood CG, Matin SF. Illness uncertainty and quality of life of patients with small renal tumors undergoing watchful waiting: A 2-year prospective study. Eur Urol 63(6):1122-1127, 6/2013. e-Pub 2/9/2013. PMID: 23419322.
31. Lim ZD, Mahajan A, Weinberg J, Tannir NM. Outcome of patients with renal cell carcinoma metastatic to the brain treated with sunitinib without local therapy. Am J Clin Oncol 36(3):258-60, 6/2013. e-Pub 3/20/2012. PMID: 22441343.
32. Margulis V, Shariat SF, Rapoport Y, Rink M, Sjoberg DD, Tannir NM, Abel EJ, Culp SH, Tamboli P, Wood CG. Development of accurate models for individualized prediction of survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. Eur Urol 63(5):947-52, 5/2013. e-Pub 11/23/2012. PMID: 23273681.
33. Karam JA, Ahrar K, Vikram R, Romero CA, Jonasch E, Tannir NM, Rao P, Wood CG, Matin SF. Radiofrequency ablation of renal tumours with clinical, radiographical and pathological results. BJU Int 111(6):997-1005, 5/2013. e-Pub 3/2013. PMCID: PMC3637414.
34. Shu X, Lin J, Wood CG, Tannir NM, Wu X. Energy balance, polymorphisms in the mTOR pathway, and renal cell carcinoma risk. J Natl Cancer Inst 105(6):424-32, 3/20/2013. e-Pub 2/2/2013. PMCID: PMC3601952.
35. Chen Y, Yao H, Thompson EJ, Tannir NM, Weinstein JN, Su X. VirusSeq: Software to identify viruses and their integration sites using next-generation sequencing of human cancer tissue. Bioinformatics 29(2):266-7, 1/15/2013. e-Pub 11/17/2012. PMCID: PMC3546792.
36. Rini B, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Dirix LY, Fishman M, Ramlau R, Ravaud A, Rogowski W, Kracht K, Sun YN, Bass MB, Puhlmann M, Escudier B. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study. Cancer 118(24):6152-61, 12/15/2012. e-Pub 6/12/2012. PMID: 22692704.
37. Tannir NM, Plimack E, Ng C, Tamboli P, Bekele NB, Xiao L, Smith L, Lim Z, Pagliaro L, Araujo J, Aparicio A, Matin S, Wood CG, Jonasch E. A phase 2 trial of sunitinib in patients with advanced non-clear cell renal cell carcinoma. Eur Urol 62(6):1013-9, 12/2012. e-Pub 6/2012. PMCID: PMC3882163.
38. Abel EJ, Carrasco A, Culp SH, Matin SF, Tamboli P, Tannir NM, Wood CG. Limitations of preoperative biopsy in patients with metastatic renal cell carcinoma: comparison to surgical pathology in 405 cases. BJU Int 110(11):1742-6, 12/2012. e-Pub 4/13/2012. PMID: 22503066.
39. Rodney AJ, Tannir NM, Siefker-Radtke AO, Liu P, Walsh GL, Millikan RE, Swisher SG, Tu SM, Pagliaro LC. Survival outcomes for men with mediastinal germ-cell tumors: The University of Texas MD Anderson Cancer Center experience. Urol Oncol 30(6):879-85, Nov-Dec, 11/2012. e-Pub 10/8/2010. PMID: 20933444.
40. Richey SL, Rao P, Wood CG, Patel S, Tannir NM. Metastatic extraosseous Ewing's sarcoma (EES)/Primitive Neuroectodermal Tumor (PNET) of the kidney: 8-year durable response after induction and maintenance chemotherapy. Clin Genitourin Cancer 10(3):210-2, 9/2012. e-Pub 4/2012. NIHMSID: NIHMSNIHMS611584.
41. Rao P, Tannir NM, Tamboli P. Expression of OCT3/4 in renal medullary carcinoma represents a potential diagnostic pitfall. Am J Surg Pathol 36(4):583-8, 4/2012. e-Pub 2012. PMID: 22301499.
42. Zurita AJ, Jonasch E, Wang X, Khajavi M, Yan S, Du DZ, Xu L, Herynk MH, McKee KS, Tran HT, Logothetis CJ, Tannir NM, Heymach JV. A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma. Ann Oncol 23(1):46-52, 1/2012. e-Pub 4/2011. PMCID: PMC3276320.
43. Cohen L, Cole SW, Sood AK, Prinsloo S, Kirschbaum C, Arevalo JM, Jennings NB, Scott S, Vence L, Wei Q, Kentor D, Radvanyi L, Tannir N, Jonasch E, Tamboli P, Pisters L. Depressive symptoms and cortisol rhythmicity predict survival in patients with renal cell carcinoma: role of inflammatory signaling. PLoS One 7(8):e42324, 2012. e-Pub 8/2012. PMCID: PMC3409855.
44. Matrana MR, Ng C, Rao P, Lim ZD, Tannir NM. Chromophobe renal cell carcinoma with sarcomatoid dedifferentiation treated with pazopanib: a case report. Clin Genitourin Cancer 9(2):137-9, 12/2011. e-Pub 8/10/2011. PMID: 21831725.
45. Abel EJ, Culp SH, Tannir NM, Tamboli P, Matin SF, Wood CG. Early primary tumor size reduction Is an independent predictor of improved overall survival in metastatic renal cell carcinoma patients treated with sunitinib. Eur Urol 60(6):1273-9, 12/2011. e-Pub 7/2011. PMID: 21784574.
46. Tannir NM, Wong YN, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, Posadas EM, Cho D, Choueiri TK, Coates A, Gupta N, Pradhan R, Qian J, Chen J, Scappaticci FA, Ricker JL, Carlson DM, Michaelson MD. Phase 2 trial of linifanib (ABT-869) in patients with advanced renal cell cancer after sunitinib failure. Eur J Cancer 47(18):2706-14, 12/2011. e-Pub 11/2011. PMID: 22078932.
47. Manoukian GE, Tannir NM, Jonasch E, Qiao W, Haygood TM, Tu SM. Pilot trial of bone-targeted therapy combining zoledronate with fluvastatin or atorvastatin for patients with metastatic renal cell carcinoma. Clin Genitourin Cancer 9(2):81-8, 12/2011. e-Pub 10/2011. PMID: 21958521.
48. Jonasch E, McCutcheon IE, Waguespack SG, Wen S, Davis DW, Smith LA, Tannir NM, Gombos DS, Fuller GN, Matin SF. Pilot trial of sunitinib therapy in patients with von Hippel-Lindau disease. Ann Oncol 22(12):2661-6, 12/2011. PMID: 22105611.
49. Milbury K, Tannir NM, Cohen L. Treatment-related optimism protects quality of life in a phase II clinical trial for metastatic renal cell carcinoma. Ann Behav Med 42(3):313-20, 12/2011. e-Pub 2011. PMID: 21822749.
50. Verma J, Jonasch E, Allen P, Tannir N, Mahajan A. Impact of tyrosine kinase inhibitors on the incidence of brain metastasis in metastatic renal cell carcinoma. Cancer 117(21):4958-65, 11/1/2011. e-Pub 4/11/2011. PMID: 21484781.
51. Monzon FA, Alvarez K, Peterson L, Truong L, Amato RJ, Hernandez-McClain J, Tannir N, Parwani AV, Jonasch E. Chromosome 14q loss defines a molecular subtype of clear cell renal cell carcinoma associated with poor prognosis. Mod Pathol 24(11):1470-9, 11/2011. e-Pub 7/1/2011. PMID: 21725288.
52. Chapin BF, Delacroix SE, Culp SH, Nogueras Gonzalez GM, Tannir NM, Jonasch E, Tamboli P, Wood CG. Safety of presurgical targeted therapy in the setting of metastatic renal cell carcinoma. Eur Urol 60(5):964-71, 11/2011. e-Pub 5/25/2011. PMID: 21621907.
53. Mathew P, Tannir N, Tu SM, Wen S, Guo CC, Marcott V, Bekele BN, Pagliaro L. Accelerated disease progression in prostate cancer and bone metastases with platelet-derived growth factor receptor inhibition: observations with tandutinib. Cancer Chemother Pharmacol 68(4):889-96, 10/2011. e-Pub 2/2011. PMID: 21290244.
54. Choueiri M, Tannir N, Jonasch E. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Curr Clin Pharmacol 6(3):144-50, 8/2011. PMID: 21827393.
55. Matrana MR, Atkinson B, Jonasch E, Tannir NM. Emerging targeted therapies in metastatic renal cell carcinoma. Curr Clin Pharmacol 6(3):189-98, 8/2011. PMID: 21827388.
56. Chowdhury S, Matrana MR, Tsang C, Atkinson B, Choueiri TK, Tannir NM. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: Recent progress and future directions. Hematol Oncol Clin North Am 25(4):853-869, 8/2011. PMID: 21763971.
57. Pagliaro LC, Tannir N, Sircar K, Jonasch E. Systemic therapy for sarcomatoid renal cell carcinoma. Expert Rev Anticancer Ther 11(6):913-20, 6/2011. PMID: 21707288.
58. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Tamboli P, Patel KK, Matin SF, Wood CG, Tannir NM. Outcome of patients with metastatic renal cell carcinoma treated with targeted therapy without cytoreductive nephrectomy. Ann Oncol 22(5):1048-53, 5/2011. e-Pub 11/29/2010. PMID: 21115604.
59. Richey SL, Ng C, Lim ZD, Jonasch E, Tannir NM. Durable remission of metastatic renal cell carcinoma with gemcitabine and capecitabine after failure of targeted therapy. J Clin Oncol 29(8):e203-5, 3/10/2011. e-Pub 12/20/2010. PMID: 21172884.
60. Jonasch E, Lal LS, Atkinson BJ, Byfield SD, Miller LA, Pagliaro LC, Feng C, Tannir NM. Treatment of metastatic renal carcinoma patients with the combination of gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center. BJU Int 107(5):741-7, 3/2011. e-Pub 9/2010. PMID: 21355978.
61. Karam JA, Rini BI, Varella L, Garcia JA, Dreicer R, Choueiri TK, Jonasch E, Matin SF, Campbell SC, Wood CG, Tannir NM. Metastasectomy after targeted therapy in patients with advanced renal cell carcinoma. J Urol 185(2):439-44, 2/2011. e-Pub 12/17/2010. PMID: 21167518.
62. Abel EJ, Culp SH, Tannir NM, Matin SF, Tamboli P, Jonasch E, Wood CG. Primary tumor response to targeted agents in patients with metastatic renal cell carcinoma. Eur Urol 59(1):10-5, 1/2011. e-Pub 10/16/2010. PMID: 20952123.
63. Dhillon J, Tannir NM, Matin SF, Tamboli P, Czerniak BA, Guo CC. Thyroid-like follicular carcinoma of the kidney with metastases to the lungs and retroperitoneal lymph nodes. Hum Pathol 42(1):146-50, 1/2011. e-Pub 10/2010. PMID: 20971497.
64. Dutcher JP, Tannir N, Bellmunt J, Escudier B. Experience with sorafenib and the elderly patient. Med Oncol 27(4):1359-70, 12/2010. e-Pub 12/2009. PMID: 20043216.
65. Jonasch E, Pagliaro LC, Tannir NM. Long-term management of patients with metastatic renal cell carcinoma on targeted agents. Expert Rev Anticancer Ther 10(12):1883-9, 12/2010. PMID: 21110755.
66. Choueiri TK, Lim ZD, Hirsch MS, Tamboli P, Jonasch E, McDermott DF, Dal Cin P, Corn P, Vaishampayan U, Heng DY, Tannir NM. Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11.2 translocation renal cell carcinoma. Cancer 116(22):5219-25, 11/15/2010. e-Pub 2010. PMID: 20665500.
67. Abel EJ, Culp SH, Matin SF, Tamboli P, Wallace MJ, Jonasch E, Tannir NM, Wood CG. Percutaneous biopsy of primary tumor in metastatic renal cell carcinoma to predict high risk pathological features: comparison with nephrectomy assessment. J Urol 184(5):1877-81, 11/2010. e-Pub 9/17/2010. PMID: 20850148.
68. Karam JA, Ahrar K, Wood CG, Jonasch E, Vikram R, Romero C, Tannir N, Matin SF. Radiofrequency ablation of renal tumors in patients with metastatic renal cell carcinoma. J Urol 184(5):1882-7, 11/2010. e-Pub 9/17/2010. PMID: 20846689.
69. Tsavachidou-Fenner D, Tannir N, Tamboli P, Liu W, Petillo D, Teh B, Mills GB, Jonasch E. Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma. Ann Oncol 21(8):1599-606, 8/2010. e-Pub 1/2010. PMID: 20089566.
70. Culp SH, Tannir NM, Abel EJ, Margulis V, Tamboli P, Matin SF, Wood CG. Can we better select patients with metastatic renal cell carcinoma for cytoreductive nephrectomy? Cancer 116(14):3378-88, 7/15/2010. PMID: 20564061.
71. Jonasch E, Tannir NM. Targeted therapy for locally advanced renal cell carcinoma. Target Oncol 5(2):113-8, 6/2010. e-Pub 7/14/2010. PMID: 20625844.
72. Mathew P, Tannir N, Tu SM, Carter CM, Bekele NB, Pagliaro L. A modular Phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer following prior taxane therapy. Cancer Chemother Pharmacol 65(4):811-5, 3/2010. e-Pub 1/2010. PMID: 20052472.
73. Ng CS, Wang X, Faria SC, Lin E, Charnsangavej C, Tannir NM. Perfusion CT in patients with metastatic renal cell carcinoma treated with interferon. Am J Roentgenol 194(1):166-71, 1/2010. PMID: 20028919.
74. Jonasch E, Corn P, Pagliaro LC, Warneke CL, Johnson MM, Tamboli P, Ng C, Aparicio A, Ashe RG, Wright JJ, Tannir NM. Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis. Cancer 116(1):57-65, 1/2010. e-Pub 10/2009. PMID: 19862815.
75. Hong D, Sebti S, Newman R, Blaskovich M, Ye L, Gagel R, Moulder S, Wheler J, Naing A, Tannir N, Ng C, Sherman S, El-Naggar A, Khan R, Trent J, Wright J, Kurzrock R. Phase I trial of a combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in advanced malignancies. Clin Cancer Res 15(22):7061-8, 11/15/2009. e-Pub 11/10/2009. PMCID: PMC2784003.
76. Chen M, Ye Y, Yang H, Tamboli P, Matin S, Tannir NM, Wood CG, Gu J, Wu X. Genome-wide profiling of chromosomal alterations in renal cell carcinoma using high-density single nucleotide polymorphism arrays. Int J Cancer 125(10):2342-8, 11/2009. e-Pub 6/2009. PMCID: PMC2768265.
77. Montero A, Diaz-Montero C, Millikan R, Liu J, Do, D-A, Hodges S, Jonasch E, McIntyre B, Hwu P, Tannir N. Cytokines and angiogenic factors in metastatic renal cell cancer: association of pretreatment serum levels with survival. Ann Oncol 20(10):1682-7, 10/2009. PMID: 19541791.
78. Jonasch E, Wood CG, Matin SF, Tu S-M, Pagliaro LC, Corn PG, Aparicio A, Tamboli P, Millikan RE, Wang X, Araujo JC Arap W, Tannir N. Phase II presurgical feasibility study of bevacizumab in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(25):4076-81, 9/2009. PMID: 19636008.
79. Rodney A, Gombos D, Fuller G, Pagliaro LC, Tannir N. Choroidal and conjunctival metastases from renal cell carcinoma. Am J Clin Oncol 32(4):448-9, 8/2009. PMID: 19657240.
80. Daliani DD, Tannir NM, Papandreou CN, Wang X, Swisher S, Wood CG, Swanson DA, Logothetis CJ, Jonasch E. Prospective assessment of systemic therapy followed by surgical removal of metastases in selected patients with renal cell carcinoma. BJU Int 104(4):456-60, 8/2009. PMID: 19338544.
81. Vikram R, Ng CS, Tamboli P, Tannir NM, Jonasch E, Matin SF, Wood C, Sandler CM. Papillary renal cell carcinoma: Radiologic-pathologic correlation and spectrum of disease. Radiographics 29(3):741-54; discussion 755-7, May-Jun, 5/2009. PMID: 19448113.
82. Plimack ER, Tannir N, Lin E, Bekele BN, Jonasch E. Patterns of disease progression in metastatic renal cell carcinoma patients treated with antivascular agents and interferon: impact of therapy on recurrence patterns and outcome measures. Cancer 115(9):1859-66, 5/2009. PMID: 19241453.
83. Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer 115(6):1310-1317, 3/2009. PMID: 19156903.
84. Clague J, Lin J, Cassidy A, Matin S, Tannir NM, Tamboli P, Wood CG, Wu X. Family history and risk of renal cell carcinoma: results from a case-control study and systematic meta-analysis. Cancer Epidemiol Biomarkers Prev 18(3):801-807, 2/2009. e-Pub 2/2009. PMID: 19240244.
85. Rodney A, Gombos D, Pagliaro LC, Tannir N. Ischemic optic neuropathy associated with low dose interferon alfa: Report of two cases. Am J Clin Oncol 32(1):86-87, 2/2009. NIHMSID: NIHMSNIHMS618553.
86. Dubauskas Z, Kunishige J, Prieto VG, Kantrow SM, Jonasch E, Hwy P, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib. Clin Genitourin Cancer 7(1):20-3, 1/2009. PMID: 19213663.
87. Margulis V, Matin SF, Tannir N, Tamboli P, Shen Y, Lozano M, Swanson DA, Jonasch E, Wood CG. A randomized trial of adjuvant thalidomide versus observation in patients with completely resected high risk renal cell carcinoma. Urology 73(2):337-41, 2009. e-Pub 10/31/2008. PMID: 18950837.
88. Aparicio A, North B, Barske L, Wang X, Bollati V, Weisenberger D, Yoo C, Horne E, Tannir N, Groshen S, Jones P, Yang A, Issa J-P. LINE-1 methylation in plasma DNA as a biomarker of activity of DNA methylation inhibitors in patients with solid tumors. Epigenetics 4(3), Apr 6, 2009. PMID: 19421002.
89. Lin J, Pu X, Wang W, Matin S, Tannir NM, Wood CG, Wu X. Case-control analysis of nucleotide excision repair pathway and the risk of renal cell carcinoma. Carcinogenesis 29(11):2112-2119, 11/2008. e-Pub 8/18/2008. PMID: 18711149.
90. Ng CS, Wood CG, Silverman PM, Tannir NM, Tamboli P, Sandler CM. Renal cell carcinoma: diagnosis, staging, and surveillance - Review. AJR Am J Roentgenol 191(4):1220-1230. Review, 10/2008. PMID: 18806169.
91. Tannir NM, Thall PF, Ng CS, Wang X, Wooten L, Siefker-Radtke A, Mathew P, Pagliaro, L, Wood C, Jonasch E. A phase II trial of gemcitabine plus capecitabine in metastatic renal cell cancer previously treated with immunotherapy and targeted agents. J Urol 180(3):867-72; discussion 872, 9/2008. NIHMSID: NIHMSNIHMS615126.
92. Bilen MA, Waguespack SG, Tannir NM, Pravinkumar SE, Tamboli P, Tu S-M. Multisystem crisis in a patient with presumptive renal cell carcinoma. Clin Genitourin Cancer 6(2):128-130, 9/2008. PMID: 18824438.
93. Jain R, Mathew P, Wood CG, Tannir NM. Sunitinib-induced acute hemolysis without hypertension: A case report. Clin Genitourin Cancer 6(2):122-123, 9/2008. PMID: 18824436.
94. Hong DS, Reddy SB, Prieto VG, Wright JJ, Tannir NM, Cohen RP, Diwan AH, Evans HL, Kurzrock R. Multiple squamous cell carcinomas of the skin after therapy with sorafenib combined with tipifarnib. Arch Dermatol 144(6):779-82, 6/2008. PMID: 18559769.
95. Jonasch E, Wood C, Tamboli P. Pagliaro LC, Tu SM, Kim J, Sirvastava P, Perez C, Isakov L, Tannir N. Vaccination of metastatic renal cell carcinoma patients with autologous tumour-derived vitespen vaccine: clinical findings. Br J Cancer 98(8):1336-41, 4/2008. PMID: 18362942.
96. Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM. Malignant transformation of testicular teratoma: A chemoresistant phenotype. Urol Oncol 26(6):595-596, Nov-Dec, 1/2008. e-Pub 1/14/2008. PMID: 18367105.
97. Jonasch E, Tannir NM. Adjuvant and neoadjuvant therapy in renal cell carcinoma. Cancer J 14(5):315-9, Sep-Oct, 2008. PMID: 18836336.
98. Khakoo AY, Kassiotis CM, Tannir N, Plana JC, Halushka M, Bickford C, Trent J 2nd, Champion JC, Durand JD, Lenihan DJ. Heart failure associated with sunitinib malate: a multitargeted receptor tyrosine kinase inhibitor. Cancer 112(11):2500-8, 2008 Jun, 2008. PMID: 18386829.
99. Margulis V, Matin SF, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG. Surgical morbidity associated with administration of targeted molecular therapies prior to cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180(1):94-8, 2008. e-Pub 5/2008. PMID: 18485389.
100. Spiess PE, Tannir NM, Brown GA, Liu P, Tu SM, Evans JG, Pisters LL. Recurrence in nonseminomatous germ cell testis tumor patients with no viable tumor at postchemotherapy retroperitoneal lymph node dissection. Urology 70(6):1173-1178, 12/2007. PMID: 18158041.
101. Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at post-chemotherapy retroperitoneal lymph node dissection: Can we predict patients at risk of disease progression? Cancer 110(12):2700-2708, 12/2007. PMID: 17948916.
102. Kassouf W, Sanchez-Ortiz R, Tamboli P, Tannir N, Jonasch E, Merchant MM, Matin SF, Swanson DA, Wood CG. Cytoreductive nephrectomy for metastatic renal cell carcinoma with non-clear histology. J Urol 178(5):1896-1900, 11/2007. e-Pub 9/2007. PMID: 17868729.
103. Small EJ, Fontana J, Tannir N, DiPaola R, Wilding G, Rubin M, Bailey Iacona R, Kabbinavar FF. A phase II trial of gefitinib in patients with non-metastatic hormone-refractory prostate cancer. BJU Int 100(4):765-769, 10/2007. PMID: 17822457.
104. Mathew P, Thall PF, Bucana CD, Oh WK, Morris MJ, Jones DM, Johnson MM, Wen S, Pagliaro LC, Tannir NM, Tu SM, Meluch AA, Smith L, Cohen L, Kim SJ, Troncoso P, Fidler IJ, Logothetis CJ. Platelet-derived growth factor receptor inhibition and chemotherapy for castration-resistant prostate cancer with bone metastases. Clin Cancer Res 13(19):5816-5824, 10/2007. PMID: 17908974.
105. Shao L, Wood CG, Zhang D, Tannir NM, Matin S, Dinney CP, Wu X. Telomere dysfunction in peripheral lymphocytes as a potential predisposition factor for renal cancer. J Urol 178(4 Pt 1):1492-1496, 10/2007. e-Pub 8/2007. PMID: 17707063.
106. Spiess PE, Pettaway CA, Vakar-Lopez F, Kassouf W, Wang X, Busby JE, Do KA, Davuluri R, Tannir NM. Treatment outcomes of small cell carcinoma of the prostate: A single-center study. Cancer 110(8):1729-1737, 10/2007. PMID: 17786954.
107. Lin PP, Mirza AN, Lewis VO, Cannon CP, Tu SM, Tannir NM, Yasko AW. Patient survival after surgery for osseous metastases from renal cell carcinoma. J Bone Joint Surg Am 89(8):1794-801, 8/2007. PMID: 17671020.
108. Thall PF, Wooten LH, Logothetis CJ, Millikan RE, Tannir NM. Bayesian and frequentist two-stage treatment strategies based on sequential failure times subject to interval censoring. Stat Med 26(26):4687-702, 4/2007. PMID: 17427204.
109. Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol 177(1):131-138, 1/2007. PMID: 17162023.
110. Nakayama K, Tannir NM, Liu P, Wathen JK, Cheng YC, Champlin RE, Ueno NT. Natural history of metastatic renal cell carcinoma in patients who underwent consultation for allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 13(8):975-985, 2007. PMID: 17640602.
111. Ebbinghaus S, Hussain M, Tannir N, Gordon M, Desai AA, Knight RA, Humerickhouse RA, Qian J, Gordon GB, Figlin R. Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma. Clin Cancer Res 13(22 Pt 1):6689-6695, 2007. PMID: 18006769.
112. Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM, Pisters LL. Surgical management of growing teratoma syndrome: the M.D. Anderson Cancer experience. J Urol 177(4):1330-1334; discussion 1334, 2007. PMID: 17382725.
113. Tannir NM, Cohen L, Wang X, Thall P, Mathew PF, Jonasch E, Siefker-Radtke A, Pagliaro LC, Ng CS, Logothetis C. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma. Cancer 107(9):2254-61, 11/2006. PMID: 17029276.
114. Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 107(7):1483-1490, 10/2006. PMID: 16944541.
115. Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: Can it be predicted using clinical parameters? Cancer 107(7):1503-1510, 10/2006. PMID: 16944534.
116. Rodney A, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes. Cancer 106(10):2143-2147, 5/2006. PMID: 16598751.
117. Tannir N, Jonasch E, Pagliaro LC, Mathew P, Siefker-Radtke A, Rhines L, Lin P, Tibbs R, Do KA, Lin SH, Tu SM. Pilot trial of bone-targeted therapy with zoledronate, thalidomide, and interferon-gamma for metastatic renal cell carcinoma. Cancer 107(3):497-505, 2006. PMID: 16795067.
118. Ahrar K, Matin S, Wood CG, Wallace MJ, Gupta S, Madoff DC, Rao S, Tannir NM, Jonasch E, Pisters LL, Rozner MA, Kennamer DL, Hicks ME. Percutaneous radiofrequency ablation of renal tumors: technique, complications, and outcomes. J Vasc Interv Radiol 16(5):679-688, 5/2005. PMID: 15872323.
119. Thall PF, Wooten LH, Tannir NM. Monitoring event times in early phase clinical trials: some practical issues. Clin Trials 2(6):467-78, 2005. PMID: 16422307.
120. Ueno NT, Cheng YC, Rondón G, Tannir NM, Gajewski JL, Couriel DR, Hosing C, de Lima MJ, Anderlini P, Khouri IF, Booser DJ, Hortobagyi GN, Pagliaro LC, Jonasch E, Giralt SA, Champlin RE. Rapid induction of complete donor chimerism by the use of a reduced-intensity conditioning regimen composed of fludarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. Blood 102(10):3829-3836, 11/2003. e-Pub 7/2003. PMID: 12881308.
121. Sanchez-Ortiz RF, Tannir N, Ahrar K, Wood CG. Spontaneous regression of pulmonary metastases from renal cell carcinoma after radio frequency ablation of primary tumor: an in situ tumor vaccine? J Urol 170(1):178-179, 7/2003. PMID: 12796677.
122. Tannir NM, Kantarjian H. Idiopathic thrombocytopenic purpura following successful treatment of acute lymphoblastic leukemia. Leuk Lymphoma 41(1-2):217-220, 3/2001. PMID: 11342378.
123. Tannir NM, Talpaz M, Ghazal H, Proothi S, Kantarjian HM. Acute pancreatitis associated with interferon alpha therapy for chronic myelogenous leukemia. Leuk Lymphoma 39(5-6):647-650, 11/2000. PMID: 11342349.
124. Hagemeister FB, Tannir N, McLaughlin P, Salvador P, Riggs S, Velasquez WS, Cabanillas F. MIME chemotherapy (methyl-GAG, ifosfamide, methotrexate, etoposide) as treatment for recurrent Hodgkin's disease. J Clin Oncol 5(4):556-561, 4/1987. PMID: 3559649.
125. Kouttab N, Tannir N, Pathak S, Berger A, Sahasrabuddhe CG, Maizel AL. Establishment of stable human T-T hybridomas. J Immunol Methods 77(1):165-172, 2/1985. PMID: 3871822.
126. Tannir N, Riggs S, Velasquez W, Samaan N, Manning J. Hypercalcemia, unusual bone lesions, and human T-cell leukemia-lymphoma virus in adult T-cell lymphoma. Cancer 55(3):615-619, 2/1985. PMID: 2981152.
127. Kouttab NM, Mehta S, Morgan J, Tannir N, Sahasrabuddhe C, Maizel AL. Lymphokines and monokines as regulators of human lymphoproliferation. Clin Chem 30(9):1539-1545, 9/1984. PMID: 6432365.
128. Tannir N, Yap HY, Hortobagyi GH, Hug V, Buzdar AU, Blumenschein GR. Sequential continuous infusion with doxorubicin and vinblastine: an effective chemotherapy combination for patients with advanced breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone. Cancer Treat Rep 68(7-8):1039-1041, 7/1984. PMID: 6547638.
129. Tannir N, Spitzer G, Dicke K, Schell F, DiStefano A, Blumenschein G. Phase I-II study of high-dose mitomycin with autologous bone marrow transplantation in refractory metastatic breast cancer. Cancer Treat Rep 68(5):805-806, 5/1984. PMID: 6426793.
130. Tannir NM, Cortas N, Allam C. A functioning catecholamine-secreting vagal body tumor. A case report and review of the literature. Cancer 52(5):932-935, 9/1983. PMID: 6347360.
131. Tannir NM, Spitzer G, Zander AR, Jagannath S, Kanojia M, Vellekoop L, McLaughlin P, Hagemeister FJ, Dicke KA. High-dose chemoradiotherapy and bone marrow transplantation in patients with refractory lymphoma. Eur J Cancer Clin Oncol 19(8):1091-1096, 8/1983. PMID: 6352279.
132. Tannir N, Hagemeister F, Velasquez W, Cabanillas F. Long-term follow-up with ABDIC salvage chemotherapy of MOPP-resistant Hodgkin's disease. J Clin Oncol 7:432-439, 7/1983. PMID: 6199478.
133. Tannir N, Spitzer G, Schell F, Legha S, Zander A, Blumenschein G. Phase II study of high-dose amsacrine (AMSA) and autologous bone marrow transplantation in patients with refractory metastatic breast cancer. Cancer Treat Rep 67(6):599-600, 6/1983. PMID: 6344995.
134. Uwaydah M, Tannir N, Kantarjian H, Osseiran M, Bal'a F. Moxalactam therapy of bacterial meningitis in adults. Antimicrob Agents Chemother 23:289-292, 2/1983. PMID: 6220673.
135. Spitzer G, Vellekoop L, Zander A, Tannir N. Autologous bone marrow transplantation in leukemia and lymphomas. J Exp Clin Cancer Res 3:317-332, 1983.
136. Salti I, Faris A, Tannir N, Khouri K. Rapid correction by 1-alpha-hydroxycholecalciferol of hemichorea in surgical hypoparathyroidism. J Neurol Neurosurg Psychiatry 45(1):89-90, 1982. PMID: 7062078.
Other Articles
1. Spiess PE, Tannir NM. Reply. Urol Oncol 27(2):218-9, Mar-Apr, 2009. PMID: 19285239.
2. Cheung YC, Tannir N, Champlin RE, Ueno NT. Allogeneic hematopoietic stem-cell transplantation for metastatic RCC. Kidney Cancer J 3(3):11-20, 2005.
3. Mehta KU, Gascon P, Tannir N, Lombardo J, Robboy SJ. Impaired bone marrow in AIDS. N J Med 86(8):623-627, 8/1989. PMID: 2685666.
4. Riggs S, Tannir N. Fatal disseminated histoplasmosis in a patient with Hodgkin’s disease. The Cancer Bulletin of the University of Texas 34(4):165—167, 1982.

Abstracts

1. Malouf G, Tannir NM. Long non-coding RNA subtype classification of clear-cell renal cell carcinoma. Proceedings Amer Assoc Can Res. In Press.
2. Matrana M, Shetty A, Teegavarapu P, Kaira S, Xiao L, Atkinson B, Corn P, Jonasch E, Tannir NM. Outcomes of unselected patients with metastatic renal cell carcinoma treated with front-line pazopanib therapy. Ann Oncol 24:2779, 10/2013.
3. Atkinson BJ, Kalra S, Wang X, Tannir NM, Jonasch E. A single-center retrospective review of outcomes associated with sunitinib alternative schedule compared to traditional schedule. J Clin Oncol 31(suppl 6):abstr 381, 2013.
4. Merrill MM, Wood CG, Tannir NM, Slack R, Babaian K, Jonasch E, Pagliaro LC, Comptom Z, Tamboli P, Sircar K, Pisters LL, Matin SF, Karam JA. Characteristics and clinical outcomes of patients with renal cell carcinoma with sarcomatoid dedifferentiation (sRCC). J Clin Oncol 31(suppl 6):abstr 401, 2013.
5. Jonasch E, Thakur S, Sircar K, Tamboli P, Tannir NM, Monzon FA. Impact of chromosomal copy number variation on outcome in metastatic clear cell renal cell carcinoma patients treated with antiangiogenic agents. J Clin Oncol 31(suppl 6):abstr 393, 2013.
6. Matrana MR, Duran C, Shetty A, Xiao L, Atkinson BJ, Corn PG, Charnsangavej C, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): Updates results. J Clin Oncol 31(suppl 6):abstr 367, 2013.
7. Babaian K, Matin SF, Tamboli P, Tannir NM, Jonasch E, Wood CG, Karam JA. Partial nephrectomy in the setting of metastatic renal cell carcinoma. J Clin Oncol 31(suppl 6):abstr 440, 2013.
8. Thompson JA, Forero A, Heath EI, Pal SK, Ansell SM, Infante JR, De Vos S, Hamlin PA, Whiting NC, Zhao B, Tannir NM. SGN-75 in the treatment of patients with CD70-positive malignancies including metastatic renal cell carcinoma. J Clin Oncol 31(suppl 6):abstr 368, 2013.
9. Conter HJ, Wood CG, Matin SF, Tamboli P, MIllikan RE, Jonasch E, Tannir NM. Ten-year follow-up of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with interferon alfa-2b (IFN) as first-line therapy: Results from a randomized trial. J Clin Oncol 31(suppl 6):abstr 365, 2013.
10. Jonasch E, Wood CG, Corn PG, Sharma P, Pagliaro LC, Aparicio A, Do K-A, Wang X, Marcott VD, Matin SF, Tannir NM. Using presurgical sunitinib to select patients with newly diagnosed metastataic clear cell renal cell carcinoma for cytoreductive nephrectomy: A phase II study. J Clin Oncol 31(suppl 6):abstr 371, 2013.
11. Burnight T, Wood CG, Tannir NM, Jonasch E, Pisters LL, Matin SF, Spelman A, Wei Q, Cohen. A randomized controlled trial of expressive writing for patients with renal cell carcinoma (RCC). J Clin Oncol 30(Suppl):abstr 9029, 2012.
12. Yennurajalingam S, Frisbee-Hume S, Delgado-Guay MO, Bull J, Phan AT, Tannir NM Litton JK, Palmer JL, Reddy AS, Hui D, Dalal S, Massie L, Vadhan-Raj S, Reddy SK, Reuben JM, Bruera E. Dexamethasone (DM) for cancer-related fatigue: A double -blinded, randomized, placebo-controlled trial. J Clin Oncol 30(Suppl):abstr 9002, 2012.
13. Cauley DH, Atkinson BJ, Ng CS, Wang X, Xiao L, Corn PG, Jonasch E, Tannir NM. Everolimus (E) and temsirolimus (T) associated penumonitis (P) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol Suppl 5(abstr 401), 2012.
14. Malouf G, Monzon FA, Couturier J, Molinie V, Escudier BJ, Camparo P, Tamboli P, Wood CG, Tannir NM. Genomic analysis of translocation renal cell carcinoma: Association of frequent 3p loss and poor outcome. J Clin Oncol 30(Suppl 5):abstr 360, 2012.
15. Ho TH, Monzon FA, Hoang A, Tamboli P, Furge KA, Kydema K, Petillo D, Teh BT, Tanir NM, Hung MC, Jonasch E. Molecular characterization of SETD2, a histone methyltransferase, in clear cell renal cell carcinoma (ccRCC). J Clin Oncol 30(Suppl):abstr 4624, 2012.
16. Chapin BF, Delaxroix SE, Kenney PA, Nogueras Gonzalez GM, Tamboli P, Jonasch E, Tannir NM, Wood CG. Nodal disease in the setting of metastatic renal cell carcinoma: Can a lymph node dissection alter outcomes?. J Clin Oncol 30(Suppl 5):abstr 386, 2012.
17. Matrana MR, Shetty AV, Atkinson BJ, Xiao L, Corn PG, Millikan RE, Jonasch E, Tannir NM. Outcomes of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with pazopanib after progression on other targeted therapies (TT): A single-institution experience. J Clin Oncol 30(Suppl):abstr 4615, 2012.
18. Nieto Y, Tannir NM, Tu S-M, Jones RB, Zurita AJ, Aparicio A, Bassett R, Margolin KA, Holmberg L, Champlin RE, Pagliaro LC. Phase Ii trial of bevacizumab (BEV)/high-dose chemotherapy (HDC) for refractory germ-cell tumors (GCT). J Clin Oncol 30(Suppl):abstr 4533, 2012.
19. Haddad H, Rini BI, Jonasch E, Tannir NM, dreicer R, Garcia JA, Wood LS, Elson P. Post-axitinib systemic therapy in metastatic renal cell carcinoma (mRCC). J Clin Oncol 30(Suppl):abstr4609, 2012.
20. Ho TH, Monzon FA, Hoang A, Tamboli P, Furge KA, Dykema K, Petillo D, Teh BT, Tannir NM, Hung M-C, Jonasch E. Regulation of SETD2, a histony methyltransferase, in advanced clear cell renal cell carcinoma (ccRCC). J Clin Oncol 30(Suppl 5):abstr 368, 2012.
21. Matrana MR, Rao P, Atkinson BJ, Guo C, Tannir NM. Therapies and outcomes of non-renal cell carcinoma (non-RCC) neoplasms of the kidney: A single-institution experieince. J Clin Oncol 30(Suppl 5):abstr 431, 2012.
22. Flaherty A, Matrana MR, Atkinson BJ, Tannir NM. Treatment of patients with metastatic renal cell carcinoma (RCC) and end-stage renal disease (ESRD) with targeted therapy (TT): A case series. J Clin Oncol 30(Suppl 5):abstr 453, 2012.
23. Rini BI, Szczylik C, Tannir NM, Koralewski P, Tomczak P, Deptala A, Kracht K, Sun Y, Puhlmann M, Escudier B. AMG 386 in combination with sorafenib in patients (pts) with metastatic renal cell cancer (mRCC): A randomized, double-blind, placebo-controlled, phase II study. J Clin Oncol 29(suppl 7):abstr 309, 2011.
24. Aparicio A, Harzstark AL, Lin E, Corn PG, Araujo JC, Tu S, Pagliaro LC, Millikan RE, Arap W, Kim J, Ryan CJ, Zurita AJ, Tannir NM, Line AM, Small EJ, Mathew P, Jones DM, Troncoso P, Thall PF, Logothetis C, Prostate Cancer Clinical Trials Consortium. Characterization of the anaplastic prostate carcinomas: A prospective two-stage phase II trial of frontline carboplatin adn docetaxel (CD) and salvage etoposide and cisplatin (EP). J Clin Oncol 29(Suppl):abstr 4666, 2011.
25. Jonasch E, Alvarez K, Peterson L, Tannir NM, Sircar K, Tamboli P, Monzon FA. Chromosome 14q imbalances and pathways associated with resistance to antiangiogenic therapy in clear cell renal cell carcinoma. j Clin Oncol 29(suppl 7):abstr 339, 2011.
26. Cauley DH, Atkinson BJ, Corn PG, Jonasch E, Tannir NM. Everolimus-associated pneumonitis (EAP) in metastatic renal cell cancer patients (mRCC): A single-center experience. J Clin Oncol 29(suppl 7):abstr 332, 2011.
27. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Matin SF, Wood CG, Tannir NM. Long-term survival of patients with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN). J Clin Oncol 29(suppl 7):abstr 346, 2011.
28. Matrana M, Atkinson B, Corn P, Jonasch E, Tannir MN. Metastatic RCC treated with pazopanib after progression on other targeted agents a single-institution experience. J Clin Oncol 29(suppl 7):abstr 351, 2011.
29. Tannir NM, Lim ZD, Rao P, Tamboli P, Atkinson B, Vaishampayan U, Plimack E, Rathmell K, Jonasch E. Outcome of patients with renal medullary carcinoma (RMC) treated in the era of targeted therapies (TT): A multicenter experience. J Clin Oncol 29(suppl 7):abstr 386, 2011.
30. Chapin BF, Wood CG, Jonasch E, Tannir N, Tamboli P, Culp SH, Delacroix SE, Gonzalez G. Timing of cytoreductive nephrectomy does not influence survival in metastatic renal cell carcinoma. Proceedings from AUA Annual Meeting, 2011.
31. Verma J, Jonasch E, Allen P. Tannir NM, Mahajan A. Tyrosine kinase inhibitors and development of brain metastasis in metastatic renal cell carcinoma: A retrospective review. J Clin Oncol 29(suppl 7):abstr 340, 2011.
32. Mahajan A, Verma JA, Jonasch E, Tannir N, Allen PK. Tyrosine kinase inhibitors and the treatment of brain metastases in metastatic renal cell carcinoma. Amer Radium Soc SS01(CNS Cancer):Abstract ID: 35411, 2011.
33. Abel E, Culp SH, Tannir NM, Matin SF, Tamboli P, Wood CG. Use of early primary tumor response to predict overall survival in patients with metastatic RCC undergoing treatment with sunitinib. J Clin Oncol 29(suppl 7):abstr 329, 2011.
34. Ilias-Khan NA, Khakoo AY, Tannir NM. A clinical and biological profile to predict risk of development of hypertension in patients with non-clear cell renal cell carcinoma treated with sunitinib. J Clin Oncol 28(15s):suppl; abstr 4601, 2010.
35. Wilhelm KL, Atkinson BJ, Khakoo AY, Tannir NM, Jonasch E. A retrospective evaluation of antiangiogenic therapy induced hypertension in metastatic renal cell carcinoma. J Clin Oncol 28:suppl; abstr e15047, 2010.
36. Monzon FA, Alvarez K , Amato RJ, Peterson L, Shen SS, Hernandez-McClain J, Sircar K, Tamboli P, Tannir NM, Jonasch E. Chromosomal imbalances as biomarkers for recurrence and antiangiogenic resistance in clear cell renal cell carcinoma. J Clin Oncol 28:suppl; abstr e15012, 2010.
37. Richey SL, Culp SH, Jonasch E, Corn PG, Pagliaro LC, Matin SF, Wood CG, Tannir NM. Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with targeted therapy (TT) without cytoreductive nephrectomy (CN). J Clin Oncol 28(15s):suppl; abstr 4613, 2010.
38. Tannir NM, Wong Y, Kollmannsberger CK, Ernstoff MS, Perry DJ, Appleman LJ, E. M. Posadas, Qian J, Ricker JL, Michaelson D. Phase II trial of linifanib in patients with advanced renal cell cancer (RCC) after sunitinib failure. J Clin Oncol 28(15s):4527, 2010.
39. Jonasch E, Wood CG, Pagliaro LC, Corn PG, Aparicio A, Marcott VD, Matin SF, Tannir NM. Presurgical sunitinib in patients with newly diagnosed metastatic renal cell carcinoma (mRCC): Interim toxicity and feasibility analysis. J Clin Oncol 28:suppl; abstr e15083, 2010.
40. Atkinson BJ, Perpich J, Tannir NM, Jonasch E. Schedule modifications and treatment outcomes for sunitinib-related adverse events. J Clin Oncol 28:suppl; abstr e15115, 2010.
41. Plimack ER, Jonasch E, Bekele BN, Qiao W, Ng CS, Tannir NM. Sunitinib in papillary renal cell carcinoma (pRCC): Results from a single-arm phase II study. J Clin Oncol 28(15s):suppl; abstr 4604, 2010.
42. Matin SF, McCutcheon IE, Gombos DS, S. Waguespack, N. M. Tannir, Wen S, Davis DW, Smith LA, Fuller G, Jonasch E. Treatment of VHL patients with sunitinib: Clinical outcomes and translational studies. J Clin Oncol 28(15s):3040, 2010.
43. Dubauskas Lim Z, Choueiri TK, Hirsch MS, Jonasch E, Vaishampayan UN, Tamboli P, Corn PG, Heng DY, Tannir NM. Vascular endothelial growth factor (VEGF)-targeted therapy for the treatment of adult metastatic Xp11 translocation renal cell carcinoma. J Clin Oncol 28(15s):suppl; abstr 4606, 2010.
44. Heymach J, Jonasch E, Wang X, Du DZ, Yan S, Xu L, Herynk MH, McKee KS, Tran HT, Tannir NM, Zurita AJ. A cytokine and angiogenic factor (CAF) plasma signature for selection of sorafenib (SR) therapy in patients (pts) with metastatic renal cell carcinoma (mRCC). J Clin Oncol 27(15s):spllu; abstr 5114, 2009.
45. Siefker-Radtke AO, Kamat AM, Williams DL, Tannir NM, Tu S. Pagliaro LC, Dinney C, Millikan RE. A phase II randomized 4-regimen selection trial incorporating response for sequential chemotherapy in metastatic, unresectable urothelial cancer: Final results from the M. D. Anderson Cancer Center. J Clin Oncol 27(15s):suppl; abstr 5071, 2009.
46. Montero AJ, Diaz-Montero CM, Liu J, Do K, Millikan RE, Tannir NM. Cytokines and angiogenic factors in metastatic renal cell cancer: Association of pre-treatment serum levels with survival. J Clin Oncol 27:suppl; abstr e16036, 2009.
47. Falchook GS, Wheler JJ, Tannir NM, Maing A, Jackson EF, Hong D, Lawhorn KN, Ng CS, Amin H, Kurzrock R. Hypoxia-inducible factor 1α (HIF-1α) modulation in combination with anti-angiogenic therapy. J Clin Oncol 27(15s):suppl; abstr 3555, 2009.
48. Richey SL, Culp SH, Wood CG, Corn PG, Jonasch E, Tannir NM. Outcome of patients (pts) with metastatic renal cell carcinoma (mRCC) treated with systemic therapy without cytoreductive nephrectomy (CN). J Clin Oncol 27:suppl; abstr e16035, 2009.
49. Atkinson B, Hart J, Lin E, Tannir N, Jonasch E. Patient characteristics associated with dose-limiting sunitinib adverse events. J Clin Oncol 27:suppl; abstr e16110, 2009.
50. Jonasch E, Tsavachidou D, Wood CG, Matin SF, Corn PG, Tamboli P, Wang X, Tannir N. Phase II presurgical study of bevacizumab plus erlotinib in untreated patients with metastatic renal cell carcinoma. J Clin Oncol 27(15s):suppl; abstr 5004, 2009.
51. Tannir N, Wong Y, Kollmannsberger C, Ernstoff MS, Perry DJ, Appleman LJ, Posadas E, Qian J, Ricker JL, Michaelson DM. Phase II trial of ABT-869 in advanced renal cell cancer (RCC) after sunitinib failure: Efficacy and safety results. J Clin Oncol 27(15s):suppl; abstr 5036, 2009.
52. Johnson ED, Tannir NM, Olejeme KA, Logothetis CJ, Jonasch E. Survival benefit in bevacizumab-based therapy in sickle cell trait patients diagnosed with renal medullary carcinoma. J Clin Oncol 27:suppl; abstr e16096, 2009.
53. Miller L, Lal LS, Tannir NM, DaCosta Byfield S, Atkinson B, Feng C, Lau JK, Yin L, Jonasch E. Treatment of poor-risk metastatic renal carcinoma patients with combination gemcitabine, capecitabine, and bevacizumab at a tertiary cancer center. J Clin Oncol 27:suppl; abstr e16112, 2009.
54. Pagliaro LC, Tannir NM, Tu S, Moomey B, Carter CM, Bekele N, Mathew P. A modular phase I study of lenalidomide and paclitaxel in metastatic castration-resistant prostate cancer with prior taxane therapy. J Clin Oncol 26:13545, May 20 suppl, 2008.
55. Tannir NM, Zurita AJ, Heymach JV, Tran HT, Pagliaro L, Corn P, Aparicio A, Ashe R, Wright JJ, Jonasch E. A randomized phase II trial of sorafenib versus sorafenib plus low-dose interferon-alfa: Clinical results and biomarker analysis. J Clin Oncol 26:5093, May 20 suppl, 2008.
56. Falchook GS, Jackson EF, Wheler JJ, Moulder SL, Hong DS, Naing A, Tannir NM, Lawhorn KN, Ng CS, Kurzrock R. Anti-angiogenic therapy in combination with hyposix-inducible factor-1α (HIF-1α) modulation. J Clin Oncol 26:14604, May 20 suppl, 2008.
57. Dubauskas Z, Kunishige J, Prieto VG, Hwu P, Jonasch E, Tannir NM. Cutaneous squamous cell carcinoma and inflammation of actinic keratoses associated with sorafenib: A single institution experience. J Clin Oncol 26:16101, May 20 suppl, 2008.
58. Plimack ER, Tannir N, Bekele BN, Lin E, Jonasch E. Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon. 2008 Genitourinary Cancers Symposium:393, 2008.
59. Araujo JC, Jonasch E, Tannir NM, Bekele BN, Lin E, Plimack ER. Patterns of progression in renal cell carcinoma: antivascular therapy compared with interferon. J Clin Oncol 26:5106, May 20 suppl, 2008.
60. Jonasch E, Wood CG, Matin S, Tamboli P, Do K. Pagliaro LC, Aparicio AM, Araujo JC, Tannir NM. Presurgical bevacizumab in patients with metastatic clear cell renal cell carcinoma: A phase II study. J Clin Oncol 26:5104, May 20 suppl, 2008.
61. Tsavachidou D, Tannir NM, Thomas C, Mills GB, Jonasch E. Reverse-phase protein array marker evaluation of protein expression patterns related to anti-angiogenesis treatment in renal cell carcinoma. J Clin Oncol 26:16016, May 20 suppl, 2008.
62. Mathew P, Pagliaro LC, Tannir NM, Tu S, Marcott V, Patterson L, Reed K, Bekele N, Logothetis CJ. Single-agent platelet-derived growth factor (PDGF) receptor inhibitor therapy for castration-resistant prostate cancer with bone metastases. J Clin Oncol 26:5164, May 20 suppl, 2008.
63. Plimack ER, Jonasch E, Bekele BN, Smith LA, Araujo JC, Tannir NM. Sunitinib in non-clear cell renal cell carcinoma (ncc-RCC): A phase II study. J Clin Oncol 26:5112, May 20 suppl, 2008.
64. Dutcher JP, Szczylik C, Tannir N, Benedetto P, Ruff P, Hsu A, Berkenblit A, Thiele A, Strahs A, Feingold J. Correlation of survival with tumor histology, age, and prognostic risk group for previously untreated patients for advanced renal cell carcinoma (adv RCC) receiving temsirolimus (TEMSR) or interferon-alpha (IFN). J Clin Oncol 25(18S):Abstract 5033, June 20 Supplement, 2007.
65. Matin S, Tannir N. Laparoscopic salvage nephrectomy after targeted neoadjuvant therapy for metastatic renal cell carcinoma: Initial results. J Clin Oncol 25(Moderated Poster Acceptance):Abstract 97323, 2007.
66. Camacho LH, Hong DS, Gutierrez C, Parker CA, Purdom MA, Tannir NM, Moulder S, Gale RP, Schwartz B, Kurzrock R. Organic arsenic in patients (pts) with advanced solid tumors: Phase 1 results of Z10-101 (s-dimethylarsino-glutathione). J Clin Oncol 25(18S):Abstract 3554, June 20 Supplement, 2007.
67. Hong DS, Camacho L, Ng C, Wright J, Newman RA, Moulder S, Tannir N, Wheler J, Khan R, Kuzrock R. Phase I study of tipifarnib and sorafenib in patients with biopsiable advanced cancers (NCI protocol 7156 supported by NCI grant U01 CA062461). J Clin Oncol 25(18S):Abstract 3549, June 20 Supplement, 2007.
68. Jonasch E, Corn P, Ashe RG, Do D, Tannir NM. Randomized phase II study of sorafenib with or without low-dose IFN in patients with metastatic renal cell carcinoma. J Clin Oncol 25(18S):Abstract 5104, June 20 Supplement, 2007.
69. Tsavachidou D, Tannir NM, Wood CG, Corn P, Do K, Tamboli P, Smith LA, Matin S, Jonasch E. Von Hippel-Lindau gene mutation status is associated with a dichotomous response in primary and metastatic tumors in patients receiving bevacizumab and erlotinib for metastatic renal cell carcinoma. J Clin Oncol 25(18S):Abstract 15522, 2007.
70. Camacho LH, Hong DS, Gutierrez C, Vertovsek S, Tannir N, Parker CA, Purdom MA, Lewis J, Gale RP, Kurzrock R. Phase 1 trial of Z10-101, a novel organic arsenic in patients with advanced cancers. J Clin Oncol 24:Abstract 13041, 2006.
71. Montero AJ, Diaz-Montero C, Wang X, McIntyre BW, Tannir N. Predictive utility of serum cytokine levels in patients with metastatic renal cell carcinoma (MRCC) treated with interferon alfa (IFNa). J Clin Oncol 24:Abstract 14503, 2006.
72. Spiess PE, Brown GA, Liu P, Tannir NM, Tu S, Kamat AM, Pisters LL. Predictors of survival in patients undergoing post-chemotherapy retroperitoneal lymph node dissectino. J Clin Oncol 24(18S):Abstract 4593, 2006.
73. Lina S, Wood CG, Zhang D, Tannir NM, Dinney CP, Wu X. Telomere dysfunction in peripheral lymphocytes as a predisposition factor for renal cancer. Proc Amer Assoc Cancer Res 26:4990, 2006.
74. Rodney AJ, Siefker-Radtke A, Tannir NM, Swisher S, Walsh G, Millikan RE, Pagliaro LC. Treatment outcomes of patients (pts) with primary mediastinal germ cell tumors (PMGCT): The M.D. Anderson Cancer Center (MDACC) experience. J Clin Oncol 24(18S):Abstract 14538, 2006.
75. Tannir NM, Jonasch E, McMichael C, Wang X, Wooten L, Ng CS. A phase II trial of gemcitabine plus capecitabine (GX) in patients with advanced renal cell cancer (mrcc) previously treated with immunotherapy. J Clin Oncol 23(16S):Abstract 4598, 2005.
76. Ebinghaus SW, Hussain M, Tannir NM, Gordon MS, Desai AA, Knight RA, Carlson DM, Giflin RA. A randomized phase 2 study of the thrombospondin-mimetic peptide ABT-510 in patients with previously untreated advanced renal cell carcinoma. J Clin Oncol 23(16S):Abstract 4607, 2005.
77. Jonasch E, Tu S-M, Tannir NM, Pagliaro LC, Mathew P, Siefker-Radtke AO, Wen S, General R, Lin S-H, Logothetis CJ. Bone-targeted therapy consisting of zoledronate, thalidomide, and gamma interferon in renal cell carcinoma: A phase II study. J Clin Oncol 23(16S):Abstract 4769, 2005.
78. Rodney AJ, Dieringer P, Mathew P, Jonasch E, Tannir N, Pagliaro LC. Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer with prior taxane exposure. J Clin Oncol 23:Abstract 4750, 2005.
79. Tannir NM, Cohen L, Wang X, Ng CS, Poulter VA, Mathew P, Siefker-Radtke AO, Jonasch E, Pagliaro LC, Millikan RE. A randomized phase III trial of low dose versus intermediate dose interferon alfa (IFN) as frontline therapy in advanced progressive renal cell cancer (RCC). J Clin Oncol 22(14S):Abstract 4607, 2004.
80. Siefker-Radtke AO, Thall PF, Tannir NM, Tu SM, Pagliaro, LC, Williams DL, Millikan, RE. Implementation of a novel statistical design to evaluate successive treatment courses for metastatic transitional cell carcinoma. A Phase II trial at the M D Anderson Cancer Center. J Clin Oncol 22(14S):Abstract 4543, 2004.
81. Ueno NT, Cheng YT, Giralt SA, RondÓn G, Gajewski JL, Tannir NM, Pagliaro LC, Hortobagyi GN, Champlin RE. Complete donor chimerism by fludarabine/melphalan in mini-allogeneic transplantation for metastatic renal cell carcinoma (RCC) and breast cancer (BC). J Clin Oncol 20:Abstract #1659, 2002.

Book Chapters

1. Kovitz C, Spiess PE, Tannir NM. Germ Cell Tumors. In: Encyclopedia of Cancer: Germany. In Press.
2. Masterson J, Fisch M and Tannir N. Palliative interventions. In: Renal Cancer. Ed(s) Eisen T. Oxford University Press: Cambridge, UK. In Press.
3. Matrana M, Atkinson B, Tannir NM. Combinatorial and sequential targeted therapy in metastatic renal cell carcinoma. In: Kidney Cancer, Principles and Practices. Ed(s) PN Lara Jr, E. Jonasch. Springer-Verlag Berlin: Berlin Heidelberg Germany, 225-239, 2012. ISBN: 978-3-642-21857-6.
4. Brooks HD, Pagliaro LC, Lim ZD, Pisters LL, Tannir NM. Germ Cell Tumors. In: The MD Anderson Manual of Medical Oncology, Second. Ed(s) HM Kantarjian, RA Wolff, CA Koller. McGraw Hill Medical, 983-1002, 2011. ISBN: 978-0-07-170106-8.
5. Jonasch E, Matin SF, Pagliaro LC, Wood CG, Tannir NM. Renal Cell Carcinoma. In: The MD Anderson Manual of Medical Oncology, Second. Ed(s) HM Kantarjian, RA Wolff, CA Koller. McGraw Hill Medical, 905-23, 2011. ISBN: 978-0-07-170106-8.
6. Chowdhury S, Matrana MR, Tsang C, Atkinson B, Choueiri TK, Tannir MN. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: Recent progress and future directions. In: Hematology/Oncology Clinics of North America: Renal Cell Cancer. 25, 4. Ed(s) GP Canellos, N Berliner; Guest Editor: TK Choueiri. W. B. Saunders Company, 853-869, 2011. ISBN: 13: 978-1-4557-1103-1.
7. Dayyani F, Tannir NM. Targeted Genitourinary Cancers. In: Targeted Therapy for Solid Tumors and Hematologic Malignancies, Cancer Etiology, Diagnosis and Treatments. Ed(s) A.Q. Cardama, D.L. Gibbons, V. Cataldo. Nova Science Publishers, Inc., 187-211, 2011. ISBN: 978-1-6171-854-3.
8. Tannir N, O'Brien S, Keating M. Diagnosis and treatment of chronic lymphocytic leukemia. In: Neoplastic Diseases of the Blood, Fourth, 83-95, 2003.
9. Tannir N, O'Brien S. Chronic Leukemias. In: Conn's Current Therapy: Latest Approved Methods Of Treatment For The Practicing Physician, 426-434, 2002.
10. Spitzer G, Zander A, Tannir N. Autologous bone marrow transplantation in human solid tumors. In: Recent Advances in Bone Marrow Transplantation. The UCLA Symposium on Molecular and Cellular Biology. 7, New Series. Ed(s) Robert Peter Gale. Alan R. Liss, Inc. New York, 615-642, 1983.

Letters to the Editor

1. Tannir NM, Thall P, Millikan RE. Reply from Authors re: Camillo Porta. How to Identify Active Novel Agents in Rare Cancers and then Make Them Available: A Need for a Paradigm Shift. Eur Urol 2012;62:1020-1: Research in Rare Tumors: A Need for a Paradigm Shift. Eur Urol 62(6):1022, 12/2012. e-Pub 8/2012. PMID: 22925576.
2. Richey SL, Culp SH, Jonasch E, Matin SF, Wood CG, Tannir NM. Reply to Benefit of cytoreductive nephrectomy in metastatic RCC: do we learn from retrospective studies and small prospective studies? Ann Oncol 22(5):1243, 5/2011. PMID: 21521725.
3. Tannir N, Cabanillas F. Bone Marrow Transplantation and Salvage Chemotherapy. J Clin Onc 1:64, 1984.

Grant & Contract Support

Title: Molecular genetic and epigenetic characterization of translocation renal-cell carcinoma (RCC): Comparison of pediatric and adult forms
Funding Source: Kidney Cancer Research Group
Role: Principal Investigator
Duration: 2/1/2012 - 1/30/2013
 
Title: Molecular genetic and epigenetic characterization of translocation renal-cell carcinoma (RCC): Comparison of pediatric and adult forms
Funding Source: Kidney Cancer Research Group
Role: Principal Investigator
Duration: 10/1/2010 - 9/30/2011

Last updated: 11/14/2014